Clinical Trial Results:
            A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) of 12 weeks treatment with 2.5mg, 5mg and 10 mg daily doses of GW501516 in subjects with low HDLc
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2004-000882-36 | 
    Trial protocol  | 
        SE FI LT DK | 
    Global completion date  | 
        
                                    20 Jun 2006
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    27 Nov 2016
                             
         | 
    
    First version publication date  | 
        
                                    27 Nov 2016
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                gsk-pad20001-synopsis-redact | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.